StemX Bio is specializing in transforming diabetes drug by developing revolutionary 3D pancreatic microtissue technology.
StemX Bio has raised $410K in total funding. The most recent round was Pre-Seed. The last funding was announced in October 2025.
StemX Bio's investors include UNIIQ, LEH.
StemX Bio is headquartered in Leiden, The Netherlands.
StemX Bio is specializing in transforming diabetes drug by developing revolutionary 3D pancreatic microtissue technology.
StemX Bio is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"StemX Bio — Funding & Investors." VCBacked, October 6, 2025, https://www.vcbacked.co/company/stemx-bio. Accessed November 12, 2026.
VCBacked. (2025). StemX Bio — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/stemx-bio
{{cite web |title=StemX Bio — Funding & Investors |url=https://www.vcbacked.co/company/stemx-bio |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at StemX Bio? Request a listing update